GLORIA

GEOMAR Library Ocean Research Information Access

X

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Online Resource
    Online Resource
    Corrigendum to Transdiagnostic assessment of repetitive negative thinking and responses to positive affect: Structure and predictive utility for depression, anxiety, and mania symptoms.’ Journal of Affective Disorders, 232, 375-384. Doi: 10.1016/j.jad.2018.02.072.
    Elsevier BV ; 2021
    In:  Journal of Affective Disorders Vol. 286 ( 2021-05), p. 371-
    Details
    In: Journal of Affective Disorders, Elsevier BV, Vol. 286 ( 2021-05), p. 371-
    Type of Medium: Online Resource
    ISSN: 0165-0327
    URL: Article
    DOI: 10.1016/j.jad.2021.03.025
    RVK:
    XA 10000
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2021
    detail.hit.zdb_id: 135449-8
    SSG: 12
    SSG: 5,2
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 2
    Online Resource
    Online Resource
    Current Landscape of Immunotherapy Trials Involving the Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Axis in Intrathoracic Tumors
    Elsevier BV ; 2021
    In:  JTO Clinical and Research Reports Vol. 2, No. 4 ( 2021-04), p. 100149-
    Details
    In: JTO Clinical and Research Reports, Elsevier BV, Vol. 2, No. 4 ( 2021-04), p. 100149-
    Type of Medium: Online Resource
    ISSN: 2666-3643
    URL: Article
    DOI: 10.1016/j.jtocrr.2021.100149
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2021
    detail.hit.zdb_id: 3052298-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 3
    Online Resource
    Online Resource
    Viable Pregnancy in a patient with metastatic melanoma treated with double checkpoint immunotherapy
    Elsevier BV ; 2018
    In:  Seminars in Oncology Vol. 45, No. 3 ( 2018-06), p. 164-169
    Details
    In: Seminars in Oncology, Elsevier BV, Vol. 45, No. 3 ( 2018-06), p. 164-169
    Type of Medium: Online Resource
    ISSN: 0093-7754
    URL: Article
    DOI: 10.1053/j.seminoncol.2018.03.003
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2018
    detail.hit.zdb_id: 189220-4
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 4
    Online Resource
    Online Resource
    Preserving and enhancing social health in neurocognitive disorders
    Ovid Technologies (Wolters Kluwer Health) ; 2021
    In:  Current Opinion in Psychiatry Vol. 34, No. 2 ( 2021-03), p. 157-164
    Details
    In: Current Opinion in Psychiatry, Ovid Technologies (Wolters Kluwer Health), Vol. 34, No. 2 ( 2021-03), p. 157-164
    Abstract: The WHO updated concept of health includes social health alongside physical and mental health. No existing reviews have examined the evidence for preserving or enhancing social health in people living with neurocognitive disorders, such as mild cognitive impairment and dementia. The present review examines recent epidemiological studies and interventions with social health outcome measures, including interventions across multiple modalities and settings, from communities to assisted living facilities. Recent findings Epidemiological evidence shows that neurocognitive disorders are associated with poorer social support, and greater social isolation and loneliness. This highlights the importance of maintaining and enhancing social health in people living with neurocognitive disorders. Group activities involving dance or music have emerging evidence indicating improvements in social health in communities and assisted living facilities. More quantitative research is required on the social health benefits of cognitive/multicomponent interventions, community social groups, exercise groups and other interventions. Several socially assistive robots are being developed to help foster social participation and require further research. Summary There is evidence that group music or dance interventions can improve social health for people living with neurocognitive disorders. Larger trials with multiple social health outcome measures are required to investigate the social health benefits of exercise, cognitive/multicomponent and community social group interventions.
    Type of Medium: Online Resource
    ISSN: 0951-7367 , 1473-6578
    URL: Article
    DOI: 10.1097/YCO.0000000000000683
    Language: English
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date: 2021
    detail.hit.zdb_id: 645162-7
    detail.hit.zdb_id: 2026976-6
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 5
    Online Resource
    Online Resource
    Real-world data of durvalumab plus chemotherapy for extended stage small cell lung cancer patients: A Chilean experience.
    American Society of Clinical Oncology (ASCO) ; 2022
    In:  Journal of Clinical Oncology Vol. 40, No. 16_suppl ( 2022-06-01), p. e20600-e20600
    Details
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, No. 16_suppl ( 2022-06-01), p. e20600-e20600
    Abstract: e20600 Background: Immunotherapy has changed the landscape for small cell lung cancer treatment. The aim of this study was to evaluate the efficacy of durvalumab plus chemotherapy in small cell lung cancer (SCLC) patients in real world experience. Methods: Eligibility criteria included, histologically confirmed extended stage SCLC (ES-SCLC), evaluable disease and no prior therapy. Patients received durvalumab plus chemotherapy until progressive disease (PD) or unacceptable toxicity. The main aim of the study was to report the efficacy and safety profile of durvalumab plus chemotherapy in patients with SCLC of our everyday clinical practice. The secondary aim was to perform subgroup analysis by clinical features. Results: From May 2020 to January of 2022, 15 patients were enrolled. The patients demographics were: median age 62 years, 67% male; 93,3% former/current smoker; 100% of patients presented with extended stage SCLC at diagnosis and 26,6% had brain metastasis at diagnosis. The most frequent sites of metastasis were distant lymph nodes 67%, liver metastasis 40% and bone metastasis 33%. Number of average cycles was 16,5. The median overall survival was 11,43 months and overall response rate (ORR) was 46%. In terms of safety profile, 73% developed treatment related adverse effects, 40% were grade 2 and 20% were grade 3. No treatment adverse effects leading to deaths were observed in our cohort of patients. Conclusions: This study represents one of the first real word experience with durvalumab plus chemotherapy in ES SCLC and the results are consistent with previously reported in clinical trials.
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    URL: Article
    DOI: 10.1200/JCO.2022.40.16_suppl.e20600
    RVK:
    XA 52760
    RVK:
    XA 10000
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2022
    detail.hit.zdb_id: 2005181-5
    detail.hit.zdb_id: 604914-X
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 6
    Online Resource
    Online Resource
    RRM1 and ERCC1 as biomarkers in patients with locally advanced and metastatic malignant pleural mesothelioma treated with continuous infusion of low-dose gemcitabine plus cisplatin
    Springer Science and Business Media LLC ; 2021
    In:  BMC Cancer Vol. 21, No. 1 ( 2021-12)
    Details
    In: BMC Cancer, Springer Science and Business Media LLC, Vol. 21, No. 1 ( 2021-12)
    Abstract: Malignant Pleural Mesothelioma (MPM) is a rare but aggressive neoplasia that usually presents at advanced stages. Even though some advances have been achieved in the management of patients with MPM, this malignancy continuous to impose a deleterious prognosis for affected patients (12–18 months as median survival, and 5–10% 5-year survival rate), accordingly, the recognition of biomarkers that allow us to select the most appropriate therapy are necessary. Methods Immunohistochemistry semi-quantitative analysis was performed to evaluate four different biomarkers (ERCC1, RRM1, RRM2, and hENT-1) with the intent to explore if any of them was useful to predict response to treatment with continuous infusion gemcitabine plus cisplatin. Tissue biopsies from patients with locally advanced or metastatic MPM were analyzed to quantitatively asses the aforementioned biomarkers. Every included patient received treatment with low-dose gemcitabine (250 mg/m 2 ) in a 6-h continuous infusion plus cisplatin 35 mg/m 2 on days 1 and 8 every 3 weeks as first-line therapy. Results From the 70 eligible patients, the mean and standard deviation (SD) for ERCC1, RRM1, RRM2 and hENT-1 were 286,178.3 ( ± 219, 019.8); 104,647.1 ( ± 65, 773.4); 4536.5 ( ± 5, 521.3); and 2458.7 ( ± 4, 983.4), respectively. Patients with high expression of RRM1 had an increased median PFS compared with those with lower expression (9.5 vs 4.8 months, p  =  〈  0.001). Furthermore, high expression of RRM1 and ERCC1 were associated with an increased median OS compared with their lower expression counterparts; [(23.1 vs 7.2 months for RRM1 p  =  〈  0.001) and (17.4 vs 9.8 months for ERCC1 p  = 0.018)]. Conclusions ERCC1 and RRM1 are useful biomarkers that predict better survival outcomes in patients with advanced MPM treated with continuous infusion of gemcitabine plus cisplatin.
    Type of Medium: Online Resource
    ISSN: 1471-2407
    URL: Article
    DOI: 10.1186/s12885-021-08287-5
    Language: English
    Publisher: Springer Science and Business Media LLC
    Publication Date: 2021
    detail.hit.zdb_id: 2041352-X
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 7
    Online Resource
    Online Resource
    Inmunotherapy related hepatitis: A retrospective study of Chilean patients.
    American Society of Clinical Oncology (ASCO) ; 2020
    In:  Journal of Clinical Oncology Vol. 38, No. 15_suppl ( 2020-05-20), p. e15144-e15144
    Details
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 38, No. 15_suppl ( 2020-05-20), p. e15144-e15144
    Abstract: e15144 Background: Immune checkpoint inhibitors (ICI) have shown dramatic efficacy in many trials of advanced solid cancer. Data of toxicity for these agents setting in Chilean patients is lacking and is of importance to confirm the tolerance of immunotherapy in different population. Immunotherapy-related hepatitis (liver irAEs) represents a diagnostic and management challenge, and its frequency varies according to various factors. We aim to report the incidence, features and treatments used to manage liver irAEs in Chilean population. Methods: A retrospective review of 139 patients with diagnosis of NSCLC, Renal Cancer, Urothelial, Melanoma, treated with ICI from April 2013 until November 2019. Baseline clinical factors (age, ECOG score, cancer type, stage, Type and number of cycles of immunotherapy, comorbidities), biochemistries and treatment received were recorded for all patients with liver irAEs. Checkpoint-inhibitor-associated liver disease was graded according to the Common Terminology Criteria for Adverse Events (CTCAE) V.4 Treatment outcomes were analyzed by measuring progression free (PFS) and overall survival (OS). Results: 32 (23%) patients developed liver irAEs. Median age at diagnosis was 62 years (range 37-86). 62% patients were male, 59% ECOG 1, 96% had de novo metastatic disease. The most frequent primary sites of cancer were Renal Cancer 71% and NSCLC 9%. 78% of patients received treatment with both anti-PD-1/PD-L1 and CTLA-4 drugs. Liver irAEs G2 and G3 were 43.7% and 56.2% respectively. 31,2% and 12,5% of patients treated with single agent immunotherapy developed G2 and G3 Liver irAEs respectively. The total averages of cycles administered were 12, 4 cycles. 28% of patients developed liver irAEs after the first cycle of treatment and 12.5% after the second cycle. 6.2% patients required hospitalization and 78.1% required treatment with steroids. Conclusions: Liver irAEs was more frequent in Chilean population than data reported on previous clinical trials with a high incidence caused by ICI monotherapy and further reinforced by combination therapy. Local registries play an important role in recognizing different patterns of toxicity according to different population. Early recognition and management of liver irAEs should be of vital importance in clinical practice and as prescribing physicians we must maintain strict vigilance of liver irAES in Chilean population.
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    URL: Article
    DOI: 10.1200/JCO.2020.38.15_suppl.e15144
    RVK:
    XA 52760
    RVK:
    XA 10000
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2020
    detail.hit.zdb_id: 2005181-5
    detail.hit.zdb_id: 604914-X
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 8
    Online Resource
    Online Resource
    A rational approach to nivolumab dosing using cost analysis.
    American Society of Clinical Oncology (ASCO) ; 2020
    In:  Journal of Clinical Oncology Vol. 38, No. 15_suppl ( 2020-05-20), p. e15101-e15101
    Details
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 38, No. 15_suppl ( 2020-05-20), p. e15101-e15101
    Abstract: e15101 Background: Immune checkpoint inhibitors have changed the landscape in oncology, offering durable responses and improved survival across several tumor types. A significant problem in many countries is access to these drugs, as the yearly treatment cost can exceed $100,000. One of the alternatives to reduce the total cost of therapy is to optimize the dosing strategy. Nivolumab was initially approved with a 3mg/kg Q2W dosage, later fixed dose nivolumab 240mg Q2W was also approved. Fixed dose regimens can lead to unnecessarily high doses for patients under 80 kg. Methods: We performed a cost analysis using weight data from 53 patients diagnosed with melanoma or metastatic renal cell carcinoma who were treated with nivolumab at our institution. With that information we generated a model which calculated the total cost if they were to receive the 240mg fixed dose regimen, versus a a cost-saving strategy as follows: all patients weighing up to 79.9Kg were to be dosed at 3mg/kg, while patients 80kg or more were to use the fixed 240mg dose. Since nivolumab is available in 100mg, 40mg and 240mg vials, there is dose wastage when using the 3mg/kg calculation, this was considered for the cost analysis. Results: The median weight of our patients was 73.6kg (range 56,0kg - 103,1kg). Analyzing individual patient data, 75% of them would receive a higher dose if treated with the fixed dose regimen, versus 3mg/kg dosing. Among them, the median comparative overdosage is 50,9mg (range 3.0mg - 87.0mg). Considering drug wastage, and a USD 12.96 per mg local price for nivolumab, treating our 53 patients with the proposed model for one year would result in USD 366.886 in cost savings, versus using the 240mg fixed dose regimen, equivalent to a 9.3% of the total treatment costs. Conclusions: Expanding access to immunotherapy is a challenge for health systems. We have shown a potential 9.3% cost savings using a rational dosing regimen for nivolumab, which could be very important in cost-constrained scenarios which many countries are facing. Considering the world average weight is 62.0kg, it is plausible than even greater cost savings could be realized in many other locations around the globe.
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    URL: Article
    DOI: 10.1200/JCO.2020.38.15_suppl.e15101
    RVK:
    XA 52760
    RVK:
    XA 10000
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2020
    detail.hit.zdb_id: 2005181-5
    detail.hit.zdb_id: 604914-X
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 9
    Online Resource
    Online Resource
    Social connections and risk of incident mild cognitive impairment, dementia, and mortality in 13 longitudinal cohort studies of ageing
    Cambridge University Press (CUP) ; 2023
    In:  International Psychogeriatrics Vol. 35, No. S1 ( 2023-12), p. 16-17
    Details
    In: International Psychogeriatrics, Cambridge University Press (CUP), Vol. 35, No. S1 ( 2023-12), p. 16-17
    Abstract: Good social connections are proposed to positively influence the course of cognitive decline by stimulating cognitive reserve and buffering harmful stress-related health effects. Prior meta-analytic research has uncovered links between social connections and the risk of poor health outcomes such as mild cognitive impairment, dementia, and mortality. These studies have primarily used aggregate data from North America and Europe with limited markers of social connections. Further research is required to explore these associations longitudinally across a wider range of social connection markers in a global setting. Research Objective: We examined the associations between social connection structure, function, and quality and the risk of our primary outcomes (mild cognitive impairment, dementia, and mortality). Method: Individual participant-level data were obtained from 13 longitudinal studies of ageing from across the globe. We conducted survival analysis using Cox regression models and combined estimates from each study using two-stage meta-analysis. We examined three social constructs: connection structure (living situation, relationship status, interactions with friends/family, community group engagement), function (social support, having a confidante) and quality (relationship satisfaction, loneliness) in relation to the risks of three primary outcomes (mild cognitive impairment, dementia, and mortality). In our partially adjusted models, we included age, sex, and education and in fully adjusted models used these variables as well as diabetes, hypertension, smoking, cardiovascular risk, and depression. Preliminary results of the ongoing study: In our fully adjusted models we observed: a lower risk of mild cognitive impairment was associated with being married/in a relationship (vs. being single), weekly community group engagement (vs. no engagement), weekly family/friend interactions (vs. not interacting), and never feeling lonely (vs. often feeling lonely); a lower risk of dementia was associated with monthly/weekly family/friend interactions and having a confidante (vs. no confidante); a lower risk of mortality was associated with living with others (vs. living alone), yearly/monthly/weekly community group engagement, and having a confidante. Conclusion: Good social connection structure, function, and quality are associated with reduced risk of incident MCI, dementia, and mortality. Our results provide actionable evidence that social connections are required for healthy ageing.
    Type of Medium: Online Resource
    ISSN: 1041-6102 , 1741-203X
    URL: Article
    DOI: 10.1017/S1041610223001734
    Language: English
    Publisher: Cambridge University Press (CUP)
    Publication Date: 2023
    detail.hit.zdb_id: 1038825-4
    detail.hit.zdb_id: 2147136-8
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 10
    Online Resource
    Online Resource
    The impact of social health on global cognition and cognitive domains: An individual participant level data meta‐analysis of longitudinal cohort studies of cognitive ageing
    Wiley ; 2022
    In:  Alzheimer's & Dementia Vol. 18, No. S11 ( 2022-12)
    Details
    In: Alzheimer's & Dementia, Wiley, Vol. 18, No. S11 ( 2022-12)
    Abstract: The Social Health and Reserve in the Dementia patient journey (SHARED) project is an international collaboration investigating the association between social health and cognitive function. We conducted an individual participant‐level meta‐analysis of the associations between social health variables and cognitive function (global cognition, memory, language, and executive function). Method We obtained individual participant level data (N = 38,641, mean age = 70.5 years, 58.49% female) from 13 longitudinal cohort studies of ageing (12 studies from the COSMIC consortium and the English Longitudinal Study of Ageing). Linear mixed models examined the impact of social health factors, namely relationship status, cohabitation, interactions with friends/family, community group engagement, perceived social support, loneliness, and having a confidante, on global cognition and cognitive domains (memory, language, and executive function). Result After controlling for age, sex, and education, we found significant associations between social health variables and slower cognitive decline over time (Mean follow up = 4.99 years, SD = 3.71 years). Compared to being single, being in a relationship was associated with slower decline in global cognition ( b = 0.0132, 95% CI: 0.0044, 0.0220), and language ( b = 0.0180, 95CI%: 0.0015, 0.0346). Living with others was associated with slower decline in global cognition ( b = 0.0089, 95% CI: 0.0039, 0.0139), and memory ( b = 0.0155, 95%CI: 0.0031, 0.0279). Compared to never interacting with friends/family, weekly interactions were associated with slower decline in global cognition ( b = 0.0178, 95% CI: 0.0021, 0.0335) and memory ( b = 0.0198, 95% CI: 0.0094, 0.0302). Other social variables (community group engagement, loneliness and having a confidante) were not associated with cognitive decline. Conclusion Good social health (specifically, being in a relationship, living with others, and interactions with friends/family) was associated with slower cognitive decline. Further research is required to investigate the causal pathways from social health to cognitive health.
    Type of Medium: Online Resource
    ISSN: 1552-5260 , 1552-5279
    URL: Issue
    URL: Article
    DOI: 10.1002/alz.v18.S11
    DOI: 10.1002/alz.061062
    Language: English
    Publisher: Wiley
    Publication Date: 2022
    detail.hit.zdb_id: 2211627-8
    detail.hit.zdb_id: 2201940-6
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...